The loss-making lithium miner appears to be on the cusp of breaking even, although it spent $44m in the past quarter.

CSL slid as much as 17% to A$176.23, its lowest level since December 2018. The stock was the biggest weight on the ASX 200, ...

The global private equity giant is pretty familiar with the business, having acquired and floated the faltering local pizza ...

Argentine stock, bond and currency markets surged on Monday after President Javier Milei’s party scored a decisive victory in ...

(Reuters) -Australian biotech CSL said on Tuesday it no longer expects to complete the spin-off of its vaccine division in fiscal 2026, citing heightened volatility in the U.S. influenza vaccine ...

Most investors obsess over finding the “right time” to invest — but markets are unpredictable. This article argues that true ...